BOSENTAN OPTIONS

six The phosphodiesterase-five inhibitor sildenafil is certified for PAH in FC I–IV during the United states of america and FC II–III in Europe. Endothelin receptor antagonists (ERAs) which includes bosentan, sitaxentan and ambrisentan are oral therapies certified for use in PAH. As no oral agent has shown superiority there remains discussion r